Travere Therapeutics Inc.

NASDAQ: TVTX · Real-Time Price · USD
18.23
0.18 (1.00%)
At close: Aug 14, 2025, 3:59 PM
18.23
0.00%
Pre-market: Aug 15, 2025, 08:59 AM EDT

Travere Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
233.18M 145.24M 212.02M 227.49M
Cost of Revenue
7.74M 11.45M 7.59M 6.78M
Gross Profit
225.43M 133.79M 204.43M 220.71M
Operating Income
-320.63M -376.74M -251.56M -139.5M
Interest Income
17.82M 21.77M 6.28M 1.99M
Pretax Income
-320.51M -376.11M -278.17M -179.68M
Net Income
-321.55M -111.4M -278.48M -180.09M
Selling & General & Admin
264.12M 265.54M 220.21M 149.88M
Research & Development
217.5M 244.99M 235.78M 210.33M
Other Expenses
75.39M n/a 974K 231K
Operating Expenses
557M 521.93M 455.99M 360.21M
Interest Expense
11.18M 11.33M 11.01M 19.68M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
557M 521.98M 463.58M 367M
Income Tax Expense
120K 223K 313K 409K
Shares Outstanding (Basic)
78.89M 74.27M 63.76M 59.83M
Shares Outstanding (Diluted)
78.89M 74.27M 63.76M 59.83M
EPS (Basic)
-4.08 -1.5 -4.37 -3.01
EPS (Diluted)
-4.08 -1.5 -4.37 -3.01
EBITDA
-265.77M -326.25M -299.42M -186.68M
EBIT
-309.33M -364.78M -320.14M -197.2M
Depreciation & Amortization
43.55M 38.53M 20.72M 26.62M